Overview

Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.
Phase:
Phase 2
Details
Lead Sponsor:
Duke University
Collaborators:
Novartis
Pfizer
Treatments:
Everolimus
Sirolimus
Sunitinib